JAK inhibitors, such as the JAK1 inhibitor itacitinib (INCB039110) and JAK1/2 inhibitor ruxolitinib, have been investigated for the treatment of r/r DLBCL, with phase I/II results already reported. This evidence concerns the gene JAK1 and diffuse large B-cell lymphoma.